Comparative immediate hemodynamic and hormonal effects of amrinone and captopril in patients with severe chronic heart failure

M. Packer, N. Medina, M. Yushak

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

To compare the responses to oral inotropic and vasodilator drugs, maximally effective doses of amrinone (300 mg over 3 hours) and captopril (25 mg orally) were administered to 21 patients with severe chronic heart failure, who had not received either agent previously. Despite similar decreases in systemic vascular resistance with both drugs, amrinone produced greater increases in cardiac index (+0.56 vs. +0.41/min/m2, p < 0.05) and smaller decreases in mean arterial pressure (-11.1 vs. -15.2 mm Hg, p < 0.05) than did captopril; three patients became symptomatically hypotensive with captopril, but none did so after amrinone. These differences were due to a significant decrease in heart rate with captopril (-6.3 beats/min, p < 0.01), whereas heart rate increased with amrinone (+4.3 beats/min, p < 0.01); the increases in stroke volume index with both drugs were similar. Despite similar decreases in left ventricular filling pressures, the decrease in mean right atrial pressure with amrinone was greater than with captopril (-5.6 vs. -3.2 mm Hg, p < 0.01). This difference was the result of the greater decrease in pulmonary arteriolar resistance, and hence in right ventricular afterload, with amrinone than with captopril, (-33% vs. -16%, respectively), p < 0.01. Despite these superior hemodynamic responses to amrinone, when patients received sequential long-term treatment with both druug during the follow-up period, only 12% of patients benefitted during therapy with amrinone, whereas 64% improved clinically with captopril. In conclusion, although the increases in forward output are greater and the hypotensive risk is less with amrinone than with captopril, these superior short-term hemodynamic effects are not translated into greater long-term clinical benefits.

Original languageEnglish (US)
Pages (from-to)8-15
Number of pages8
JournalAmerican Journal of the Medical Sciences
Volume291
Issue number1
StatePublished - 1986

Fingerprint

Amrinone
Captopril
Heart Failure
Hemodynamics
Heart Rate
Atrial Pressure
Ventricular Pressure
Vasodilator Agents
Pharmaceutical Preparations
Vascular Resistance
Stroke Volume
Arterial Pressure

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Comparative immediate hemodynamic and hormonal effects of amrinone and captopril in patients with severe chronic heart failure. / Packer, M.; Medina, N.; Yushak, M.

In: American Journal of the Medical Sciences, Vol. 291, No. 1, 1986, p. 8-15.

Research output: Contribution to journalArticle

@article{0085da548e9843b392f490afb011c46b,
title = "Comparative immediate hemodynamic and hormonal effects of amrinone and captopril in patients with severe chronic heart failure",
abstract = "To compare the responses to oral inotropic and vasodilator drugs, maximally effective doses of amrinone (300 mg over 3 hours) and captopril (25 mg orally) were administered to 21 patients with severe chronic heart failure, who had not received either agent previously. Despite similar decreases in systemic vascular resistance with both drugs, amrinone produced greater increases in cardiac index (+0.56 vs. +0.41/min/m2, p < 0.05) and smaller decreases in mean arterial pressure (-11.1 vs. -15.2 mm Hg, p < 0.05) than did captopril; three patients became symptomatically hypotensive with captopril, but none did so after amrinone. These differences were due to a significant decrease in heart rate with captopril (-6.3 beats/min, p < 0.01), whereas heart rate increased with amrinone (+4.3 beats/min, p < 0.01); the increases in stroke volume index with both drugs were similar. Despite similar decreases in left ventricular filling pressures, the decrease in mean right atrial pressure with amrinone was greater than with captopril (-5.6 vs. -3.2 mm Hg, p < 0.01). This difference was the result of the greater decrease in pulmonary arteriolar resistance, and hence in right ventricular afterload, with amrinone than with captopril, (-33{\%} vs. -16{\%}, respectively), p < 0.01. Despite these superior hemodynamic responses to amrinone, when patients received sequential long-term treatment with both druug during the follow-up period, only 12{\%} of patients benefitted during therapy with amrinone, whereas 64{\%} improved clinically with captopril. In conclusion, although the increases in forward output are greater and the hypotensive risk is less with amrinone than with captopril, these superior short-term hemodynamic effects are not translated into greater long-term clinical benefits.",
author = "M. Packer and N. Medina and M. Yushak",
year = "1986",
language = "English (US)",
volume = "291",
pages = "8--15",
journal = "The American journal of the medical sciences",
issn = "0002-9629",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Comparative immediate hemodynamic and hormonal effects of amrinone and captopril in patients with severe chronic heart failure

AU - Packer, M.

AU - Medina, N.

AU - Yushak, M.

PY - 1986

Y1 - 1986

N2 - To compare the responses to oral inotropic and vasodilator drugs, maximally effective doses of amrinone (300 mg over 3 hours) and captopril (25 mg orally) were administered to 21 patients with severe chronic heart failure, who had not received either agent previously. Despite similar decreases in systemic vascular resistance with both drugs, amrinone produced greater increases in cardiac index (+0.56 vs. +0.41/min/m2, p < 0.05) and smaller decreases in mean arterial pressure (-11.1 vs. -15.2 mm Hg, p < 0.05) than did captopril; three patients became symptomatically hypotensive with captopril, but none did so after amrinone. These differences were due to a significant decrease in heart rate with captopril (-6.3 beats/min, p < 0.01), whereas heart rate increased with amrinone (+4.3 beats/min, p < 0.01); the increases in stroke volume index with both drugs were similar. Despite similar decreases in left ventricular filling pressures, the decrease in mean right atrial pressure with amrinone was greater than with captopril (-5.6 vs. -3.2 mm Hg, p < 0.01). This difference was the result of the greater decrease in pulmonary arteriolar resistance, and hence in right ventricular afterload, with amrinone than with captopril, (-33% vs. -16%, respectively), p < 0.01. Despite these superior hemodynamic responses to amrinone, when patients received sequential long-term treatment with both druug during the follow-up period, only 12% of patients benefitted during therapy with amrinone, whereas 64% improved clinically with captopril. In conclusion, although the increases in forward output are greater and the hypotensive risk is less with amrinone than with captopril, these superior short-term hemodynamic effects are not translated into greater long-term clinical benefits.

AB - To compare the responses to oral inotropic and vasodilator drugs, maximally effective doses of amrinone (300 mg over 3 hours) and captopril (25 mg orally) were administered to 21 patients with severe chronic heart failure, who had not received either agent previously. Despite similar decreases in systemic vascular resistance with both drugs, amrinone produced greater increases in cardiac index (+0.56 vs. +0.41/min/m2, p < 0.05) and smaller decreases in mean arterial pressure (-11.1 vs. -15.2 mm Hg, p < 0.05) than did captopril; three patients became symptomatically hypotensive with captopril, but none did so after amrinone. These differences were due to a significant decrease in heart rate with captopril (-6.3 beats/min, p < 0.01), whereas heart rate increased with amrinone (+4.3 beats/min, p < 0.01); the increases in stroke volume index with both drugs were similar. Despite similar decreases in left ventricular filling pressures, the decrease in mean right atrial pressure with amrinone was greater than with captopril (-5.6 vs. -3.2 mm Hg, p < 0.01). This difference was the result of the greater decrease in pulmonary arteriolar resistance, and hence in right ventricular afterload, with amrinone than with captopril, (-33% vs. -16%, respectively), p < 0.01. Despite these superior hemodynamic responses to amrinone, when patients received sequential long-term treatment with both druug during the follow-up period, only 12% of patients benefitted during therapy with amrinone, whereas 64% improved clinically with captopril. In conclusion, although the increases in forward output are greater and the hypotensive risk is less with amrinone than with captopril, these superior short-term hemodynamic effects are not translated into greater long-term clinical benefits.

UR - http://www.scopus.com/inward/record.url?scp=0022868251&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022868251&partnerID=8YFLogxK

M3 - Article

VL - 291

SP - 8

EP - 15

JO - The American journal of the medical sciences

JF - The American journal of the medical sciences

SN - 0002-9629

IS - 1

ER -